Achieving


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
23 04 2020
Historique:
pubmed: 11 4 2020
medline: 25 9 2020
entrez: 11 4 2020
Statut: ppublish

Résumé

Deregulation of the transcriptional repressor BCL6 enables tumorigenesis of germinal center B-cells, and hence BCL6 has been proposed as a therapeutic target for the treatment of diffuse large B-cell lymphoma (DLBCL). Herein we report the discovery of a series of benzimidazolone inhibitors of the protein-protein interaction between BCL6 and its co-repressors. A subset of these inhibitors were found to cause rapid degradation of BCL6, and optimization of pharmacokinetic properties led to the discovery of 5-((5-chloro-2-((3

Identifiants

pubmed: 32275432
doi: 10.1021/acs.jmedchem.9b02076
pmc: PMC7184563
doi:

Substances chimiques

BCL6 protein, human 0
Benzimidazoles 0
Proto-Oncogene Proteins c-bcl-6 0
benzimidazolone 20662-53-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4047-4068

Subventions

Organisme : Cancer Research UK
ID : C309/A11566
Pays : United Kingdom

Références

Nat Med. 2004 Dec;10(12):1329-35
pubmed: 15531890
J Med Chem. 2010 Jul 22;53(14):5061-84
pubmed: 20345171
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Cell. 2010 Apr 13;17(4):400-11
pubmed: 20385364
Cell Res. 2016 Apr;26(4):484-98
pubmed: 27002218
Biochem J. 2017 Mar 15;474(7):1127-1147
pubmed: 28298557
Angew Chem Int Ed Engl. 2015 Aug 10;54(33):9659-62
pubmed: 26083457
Pathol Biol (Paris). 2007 Feb;55(1):73-83
pubmed: 16815642
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
J Clin Invest. 2016 Sep 1;126(9):3351-62
pubmed: 27482887
Bioorg Med Chem. 2017 Sep 1;25(17):4876-4886
pubmed: 28760529
Nat Rev Drug Discov. 2017 Feb;16(2):101-114
pubmed: 27885283
Drug Discov Today. 2016 Jul;21(7):1139-46
pubmed: 27210724
Drug Discov Today. 2010 Aug;15(15-16):648-55
pubmed: 20570751
Immunol Rev. 2012 May;247(1):172-83
pubmed: 22500840
ACS Chem Biol. 2018 Nov 16;13(11):3131-3141
pubmed: 30335946
Cell Rep. 2017 Sep 19;20(12):2860-2875
pubmed: 28930682
J Med Chem. 2017 May 25;60(10):4386-4402
pubmed: 28485934
Expert Opin Drug Discov. 2019 Mar;14(3):221-230
pubmed: 30675823
Nat Chem Biol. 2015 Aug;11(8):611-7
pubmed: 26075522
J Med Chem. 2017 May 25;60(10):4358-4368
pubmed: 28471657
Blood. 2009 Apr 9;113(15):3397-405
pubmed: 18927431
Oncotarget. 2016 Nov 22;7(47):77444-77456
pubmed: 27764808
Mol Cell. 2008 Feb 15;29(3):384-91
pubmed: 18280243
Trends Mol Med. 2014 Jun;20(6):343-52
pubmed: 24698494

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH